24/7 Wall St. on MSN33m
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...
Hosted on MSN1h
What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle
Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...